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http://dx.doi.org/10.1016/j.kjms.201Abstract Terlipressin, an analogue of vasopressin, is frequently used for the management of
esophageal varices bleeding and hepatorenal syndrome. Terlipressin therapy in portal hyper-
tensive patients is frequently associated with hyponatremia, but is rarely accompanied with
serious neurological manifestations. A 39-year-old female with pancreatic neuroendocrine tu-
mor, liver metastasis, main portal vein thrombosis, and a history of esophageal varices pre-
sented to the emergency room because of hematemesis. Terlipressin was given with a
loading dose of 2 mg followed by 1 mg every 6 hours. After a total of 6 mg terlipressin injec-
tion, she suffered from acute delirium. Pertinent examinations showed there was no gross
brain lesion by computed tomography, whereas her serum sodium level dropped from baseline
(136 mmol/L) to 116 mmol/L with a serum osmolality of 256 mOsm/kg. At that time, urine so-
dium and urine osmolality were 142 mmol/L and 488 mOsm/kg, respectively. Under the tenta-
tive diagnosis of terlipressin-induced hyponatremic encephalopathy, terlipressin was withheld
and hypertonic saline infusion was given. Within 12 hours, her serum sodium level recovered to
130 mmol/L and she gradually regained her cognitive functions. Although symptomaticephrology, Department of Medicine, Kaohsiung Medical University Hospital, Number 100, Tzyou 1st
.tw (M.-C. Kuo).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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692 Y.-K. Wang et al.hyponatremic encephalopathy is a rare complication of terlipressin treatment, close moni-
toring of serum electrolyte level is warranted in patients receiving terlipressin.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Terlipressin, an analogue of vasopressin with powerful
agonistic activity on arginine vasopressin type 1 receptor
(AVPR1), can cause splanchnic vasoconstriction to result in
a significant (around 30%) decrease of hepatic blood flow
and portal venous flow in portal hypertensive patients. It is
an efficient treatment for variceal bleeding and hep-
atorenal syndrome, two major serious complications, in
patients with cirrhosis [1,2]. Terlipressin can also act on
arginine vasopressin type 2 receptor (AVPR2) to enhance
the water permeability of renal tubules by 8e10-fold to
cause antidiuresis [3], leading to water retention and
potentially hyponatremia.
Hyponatremia is a frequently encountered electrolyte
disorder in advanced cirrhotic patients secondary to the
nonosmotic release of antidiuretic hormone. Therefore,
terlipressin-induced asymptomatic hyponatremia can be
easily ignored in cirrhotic patients during terlipressin ther-
apy. In one recent prospective study, Sola` et al. [4] showed
that patients who developed terlipressin-induced hypona-
tremia had less advanced liver disease than thosewhodid not
develop hyponatremia. In addition, genetic defect at AVPR2,
which augments the vasopressin function and results in
excessive water retention [5], is suggested as a precipitating
factor for terlipressin-induced hyponatremia.
We report the occurrence of terlipressin-induced hypo-
natremic encephalopathy in a noncirrhotic patient. The
observation highlights the importance of carefully moni-
toring plasma sodium level in patients receiving terlipressin
therapy.Figure 1. Clinical course with series serum and urine elec-
trolyte changes in the patient reveals a drastic increase of
natriuresis with a drop in serum sodium level after terlipressin
administration, and diminishing of urine sodium excretion with
prompt recovery of serum sodium level after withholding ter-
lipressin administration.Case report
A 39-year-old female with pancreatic neuroendocrine
tumor with liver metastasis and main portal vein thrombosis
presented to our emergency department with hematemesis
and black stool over the past 2 days. She had no history of
hepatitis B or C infection, and previous study showed no
radiological evidence of cirrhosis. However, esophageal
varices and gastric varices were noted on previous esoph-
agogastroduodenoscopy (EGD) examination. On arrival,
physical examination revealed the following details: blood
pressure 105/74 mmHg, heart rate 86 beats/min, respira-
tory rate 16 breaths/min, and body temperature 36.3C.
Pertinent laboratory tests showed positive fecal occult
blood test, hemoglobin 7.6 g/dL, white blood cell count
10,800/mL, platelet count 104,000/mL, prothrombin time
11.3 seconds (international normalized ratio: 1.11), aspar-
tate aminotransferase 32 IU/L, alanine aminotransferase
36 IU/L, total bilirubin 0.5 mg/dL, albumin 4.04 g/dL,
serum creatinine 0.52 mg/dL, blood urea nitrogen 10 mg/dL, serum sodium 136 mmol/L, and serum potassium
3.7 mmol/L. Under the tentative diagnosis of variceal
bleeding, terlipressin was initiated with a bolus loading
dose of 2 mg, followed by 1 mg every 6 hours after
admission. Thirty-six hours later, the patient appeared in
an acute delirium state with cognitive deficits and severe
disorganization of behavior. An emergent computed to-
mography scan of the brain revealed neither apparent
intracranial lesion nor brain edema. However, blood
biochemistry examination showed hypoosmotic hypona-
tremia (serum sodium 116 mmol/L, serum osmolality
256 mOsm/kg) with natriuresis and antidiuresis (urine so-
dium 142 mmol/L, urine osmolality 488 mOsm/kg), a profile
resembling syndrome of inappropriate antidiuretic hor-
mone (SIADH), and hyperammonemia (126 mg/dL). This
patient did not have ascites, and no diuretic was used prior
to or during the hyponatremic period. Under the diagnosis
of terlipressin-induced hyponatremic encephalopathy, ter-
lipressin was immediately withheld and hypertonic saline
infusion was given.
Within 12 hours after terlipressin withdrawal and hyper-
tonic saline infusion, thepatientgradually recovered fromthe
delirium state and serum sodium level was also found to in-
crease dramatically to 130 mmol/L. Hypertonic saline infu-
sion was stopped when the patient’s consciousness had
improved. Her serum sodium further improved to 140mmol/L
with full recovery of consciousness within the next 24 hours
(Fig. 1). Brain magnetic resonance imaging with gadolinium
diethylenetriaminepentaacetic acidenhancement showedno
evidence of acute infarction, hemorrhage, or space-
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as a complication of acute change in serum sodium level in
chronic hyponatremia, was detected by brain magnetic
resonance imaging, even though the serum sodium level had
once increased to more than 10 mmol/L within 12 hours. The
patient underwent esophagogastroduodenoscopy 3 days after
recovery, and esophageal and gastric varices were found.
Varices were suspected to be the bleeder for this upper
gastrointestinal bleeding episode. The patient’s general
condition was stable after recovery from hyponatremia. No
apparent sequelae or complications were found prior to her
discharge and during follow-up at our outpatient clinic for the
consecutive 24 weeks. To investigate the mechanism of such
drastic antidiuretic and natriuretic responses to terlipressin
therapy in this patient, a genetic testing for AVPR2 mutation
was performed after a signed informed consent was given. In
brief, we collected her peripheral blood mononuclear cells,
extracted the genomicDNA, andperformedpolymerase chain
reaction and sequencing of the AVPR2 coding region. How-
ever, we did not find any mutation, variant, or single-
nucleotide polymorphism in this patient (Fig. 2).Discussion
The arginine vasopressin analogue, terlipressin, is the
treatment of choice for variceal bleeding. The mechanism
is to reduce portal venous inflow by mediating splanchnicFigure 2. Genomic DNA sequencing shows no variant or single nuc
2 receptor coding sequence.vasoconstriction through acting on the AVPR1 receptor.
However, terlipressin may concurrently activate the AVPR2
receptor, which enhances aquaporin-2 incorporating to the
luminal membrane in the renal collecting duct. Therefore,
free-water clearance and serum sodium level are
decreased [3], and hypervolemic hyponatremia and/or
water intoxication may happen as a result.
Many studies have shown that the development of
hyponatremia is not uncommon in patients treated with
terlipressin. A double-blind controlled trial by Feu et al. [6]
reported that hyponatremia occurred in 6% of patients
treated with terlipressin; and in another multicenter
controlled trial, which enrolled 106 cirrhotic patients
treated with terlipressin, there were four cases with
hyponatremia [7]. Previous studies found rapid recovery
from hyponatremia after terlipressin withdrawal, and this
phenomenon strongly suggested that terlipressin could be
the cause of hyponatremia during the treatment for vari-
ceal bleeding [4,8]. In this study case, the clinical and
laboratory evidence strongly suggested that terlipressin
was the cause of hyponatremia. It could be further
confirmed by rechallenge with terlipressin, but for safety
considerations, this is not allowed.
Terlipressin-induced hyponatremia is theoretically
caused by activating the renal AVPR2 receptor, which in-
creases reabsorption of water from the renal collecting duct
and leads to a decrease in plasma osmolality and serum so-
dium [9]. In our case, we found both antidiuretic andleotide polymorphism in the patient’s arginine vasopressin type
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patient suffered from delirium, initial laboratory tests
showed both natriuresis and antidiuresis, including hypo-
osmotic hyponatremia (plasma osmolality, 256 mOsm/kg)
with relative high urine osmolality (urine osmolality,
488mOsm/kg), relative high urine sodium (142mmol/L), and
fractional excretion of sodium (FeNa, 1.8%). Withdrawal of
terlipressin resulted in immediate recovery of serum so-
dium, urine osmolality, and urine sodium (Fig. 1). These
findings strongly suggested the association between hypo-
natremia and terlipressin in this case. In handling this pa-
tient, the unanticipated rapid recovery in serum sodium is
attributed to the dual effect of hypertonic saline and with-
drawal of terlipressin. Fortunately, central pontine myeli-
nolysis did not occur in this patient, and even the speed of
correction was more rapid than the usual recommendation.
According to this experience, more frequent monitoring of
serum sodium level during the treatment of terlipressin-
induced hyponatremia still needs to be emphasized.
Sola` et al. [4] reported that the reduction in serum so-
dium was related to baseline serum sodium and Model for
End-Stage Liver Disease (MELD) score. Patients with low
MELD scores and normal or near-normal baseline serum
sodium concentration had the highest risk [4]. Our patient
initially had a normal serum sodium level (136 mmol/L) and
a low MELD score (6 points), which was compatible with the
result of Sola` et al. [4]. Other risk groups in developing
hyponatremic encephalopathy are patients who suffer a
hypoxic event and premenopausal women [10]. More
importantly, physicians should be aware of the early sign of
hyponatremic encephalopathy (such as headache, nausea,
and vomiting) in susceptible patient groups during terli-
pressin treatment, even if their serum sodium level is
greater than 130 mmol/L at that time [11].
Cirrhotic patients are prone to suffer hyponatremia. The
plasma level of vasopressin is higher in cirrhotic patients
than in healthy individuals, and the vasopressin level in-
creases in parallel with the stage of cirrhosis [12]. In
healthy individuals, the escape from vasopressin-induced
antidiuresis can be observed by the downregulation of the
kidney aquaporin-2 channel and AVPR2 despite high plasma
AVP levels [13]. Therefore, mutations of AVPR2 may induce
hyponatremia, which has been reported as nephrogenic
syndrome of inappropriate antidiuresis (NSIAD) [14e16].
NSIAD has the same clinical picture as SIADH except for
undetectable AVP levels. We performed polymerase chain
reaction and sequencing of the AVPR2 gene coding region in
an attempt to demonstrate a possible mutation of AVPR2 to
explain the exaggerated result of water retention effect of
terlipressin, but no variant or single nucleotide poly-
morphism was found in our case.
In summary, terlipressin-induced hyponatremia is easily
ignoredandhyponatremicencephalopathy is life-threatening.
This may happen in the absence of AVPR2 mutation. Serumsodium level during terlipressin treatment should be
frequently monitored, even in noncirrhotic patients.References
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